Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Express Scripts
Merck
McKinsey
Dow

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 5,557,032

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 5,557,032
Title: Knockout mice
Abstract:Mice lacking expression of CD28 or particular CD45 isoforms in certain cells of the immune system are provided. Also provided are methods of using these mice.
Inventor(s): Mak; Tak W. (Toronto, CA)
Assignee: Ontario Cancer Institute (Toronto, CA) Thompson; Craig Bernie (Chicago, IL)
Application Number:08/451,691
Patent Claims:1. A mutant mouse, wherein its endogenous CD28 gene has been disrupted by homologous recombination using a DNA construct comprising intron 1 and exon 2 of the CD28 gene, and wherein a marker sequence is inserted into exon 2, and wherein said disruption prevents expression of CD28 on its T-cells and results in a decreased IgG titer upon viral infection.

2. The mouse of claim 1 wherein said marker sequence is the neo gene and wherein said neo gene is substituted for the region between the XbaI site of intron 1 and the EcoRI site of exon 2.

3. A method of screening a drug for immunomodulatory effects, comprising:

(a) administering the drug to the mouse of claim 1; and

(b) assaying the mouse for immunomodulation.

Details for Patent 5,557,032

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Sign up for a Free Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Sign up for a Free Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
AstraZeneca
Johnson and Johnson
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.